Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from TherapeuticsMD ( (TXMD) ) is now available.
On August 12, 2025, TherapeuticsMD announced its financial results for the second quarter ending June 30, 2025. The company reported a net income of $545 thousand, a significant improvement from a net loss in the same quarter of 2024. License revenue increased to $1.0 million, primarily due to changes in sales of licensed products, while operating expenses decreased by 45.5% compared to the previous year. The company is exploring strategic alternatives, including potential mergers or acquisitions, but has not committed to any specific timeline or outcome.
Spark’s Take on TXMD Stock
According to Spark, TipRanks’ AI Analyst, TXMD is a Neutral.
TherapeuticsMD is undergoing significant challenges, with financial difficulties being the primary concern due to declining revenues and profitability issues. The technical analysis indicates some short-term momentum but struggles over the longer term. Valuation metrics are not attractive, with a negative P/E ratio and no dividend yield. Corporate events provide a glimmer of hope, with reduced losses and strategic initiatives suggesting potential future improvements. However, the overall outlook remains cautious.
To see Spark’s full report on TXMD stock, click here.
More about TherapeuticsMD
TherapeuticsMD, Inc., previously a women’s healthcare company, transitioned in December 2022 to a pharmaceutical royalty company, primarily focused on collecting royalties from its licensees. The company no longer engages in research and development or commercial operations.
Average Trading Volume: 39,762
Technical Sentiment Signal: Strong Sell
Current Market Cap: $12.5M
For detailed information about TXMD stock, go to TipRanks’ Stock Analysis page.